Exabis Library
Welcome to the e-CCO Library!
P721 Early vedolizumab trough levels are associated with induction therapy outcome
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P721: A switch in the prevalence ratio of Crohn's disease vs. ulcerative colitis in Israel between 2003 and 2015 – a report from the epi-IIRN group
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P721: Effect of thalidomide on clinical remission in adult with refractory crohn disease, a multicentre, randomised, double-blind clinical trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P721: Faecal microbiota analysis with body composition and nutritional habits simultaneously amongst Crohn’s disease patients
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P721: Psychological care is needed and welcomed by patients with inflammatory bowel disease under routine care
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P721: Treatment of Ulcerative Colitis with OSE-127 (lusvertikimab), a Strict IL-7Rα Antagonist, Non-Cytotoxic Monoclonal Antibody
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P722 Upadacitinib was not associated with anaemia in patients with moderately to severely active ulcerative colitis: Results from the U-ACHIEVE study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P722: Compositional differences of gut microbiome using taxonomic profiling in patients with ulcerative colitis after treatment with vedolizumab
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P722: Prediagnostic serum vitamin D levels and risk of inflammatory bowel disease: a pan-European, nested case-control study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P722: Results of the STAR study: management of ulcerative colitis in private practice in france, in the first years following diagnosis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P722: Symptom-based disease trajectories Identify a population of early super-responders in ulcerative colitis achieving complete disease control under targeted therapy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P722: Trough levels, drug switching and antidrug antibody loss: Analysis of real-life infliximab and adalimumab data in IBD
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P723 Therapeutic thresholds for golimumab serum concentrations during induction and maintenance: Results from the GO-LEVEL study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P723: Comparison of the Persistence Rates of Biologic Agents in Paediatric Crohn's Disease Patients (Japanese Paediatric IBD Registry Study)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P723: Effectiveness and persistence of vedolizumab in patients with Inflammatory bowel Disease: Results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P723: Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with iron isomaltoside or ferric carboxymaltose: results of a prospective cluster randomised cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P723: SexIDI study – sexual satisfaction in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P724 Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P724: Appendectomy is not a treatment option for ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P724: Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease: Results from a prospective study (SECURE)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM